Conformational states of the corticotropin releasing factor 1 (CRF1) receptor:: detection, and pharmacological evaluation by peptide ligands

被引:26
作者
Hoare, SRJ
Sullivan, SK
Pahuja, A
Ling, N
Crowe, PD
Grigoriadis, DE
机构
[1] Neurocrine Biosci Inc, Dept Pharmacol, San Diego, CA 92121 USA
[2] Neurocrine Biosci Inc, Dept Peptide Chem, San Diego, CA 92121 USA
关键词
corticotrophin releasing factor; ligand binding; G-protein-coupled receptor; urocortin; guanine nucleotide; sauvagine; agonist;
D O I
10.1016/j.peptides.2003.09.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Previous corticotropin releasing factor 1 (CRF1) receptor characterization has been performed using radiolabeled agonists, which bind predominantly the receptor-G-protein complex. The pharmacological profile of other receptor states, and their abundance, remain poorly characterized. Here we investigated the affinity states of the CRF1 receptor heterologously expressed in Ltk(-) cells and endogenously expressed in rat cerebellum. In L-CRF1 cell membranes, three agonist affinity states were detected: a very-high affinity receptor-G-protein complex state (eliminated by GTP-gammaS) bound by [I-125]sauvagine (43pM, RG); a high affinity state insensitive to GTPgammaS bound by [I-125]sauvagine (1.4nM, termed R-O); and a low affinity G-protein-uncoupled state detected by sauvagine displacement of [I-125]astressin, a labeled antagonist (120nM, R). The relative abundance of RG:R-O:R was 18%:16%:66%. All three states were demonstrated in rat cerebellum with similar relative abundance (15%:16%:69%). The R state bound CRF with low affinity (270-330 nM), displayed a novel rank order of ligand affinity, and represented the majority of the receptor population in both receptor preparations. This study provides a framework to identify CRF1 receptor conformational states in various receptor preparations. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:1881 / 1897
页数:17
相关论文
共 50 条
[1]   Differential responsiveness of CRF receptor subtypes to N-terminal truncation of peptidic ligands [J].
Brauns, O ;
Brauns, S ;
Zimmermann, B ;
Jahn, O ;
Spiess, J .
PEPTIDES, 2002, 23 (05) :881-888
[2]   IDENTIFICATION OF A 7 TRANSMEMBRANE HELIX RECEPTOR FOR CORTICOTROPIN-RELEASING FACTOR AND SAUVAGINE IN MAMMALIAN BRAIN [J].
CHANG, CP ;
PEARSE, RV ;
OCONNELL, S ;
ROSENFELD, MG .
NEURON, 1993, 11 (06) :1187-1195
[3]  
Chen C, 1996, J MED CHEM, V39, P4358
[4]   EXPRESSION CLONING OF A HUMAN CORTICOTROPIN-RELEASING-FACTOR RECEPTOR [J].
CHEN, RP ;
LEWIS, KA ;
PERRIN, MH ;
VALE, WW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (19) :8967-8971
[5]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[6]  
Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924
[7]  
Dautzenberg FM, 2001, J PHARMACOL EXP THER, V296, P113
[8]  
DELEAN A, 1980, J BIOL CHEM, V255, P7108
[9]  
DESOUZA EB, 1987, J NEUROSCI, V7, P88
[10]   Corticotropin releasing factor (CRF) receptor modulators: Progress and opportunities for new therapeutic agents [J].
Gilligan, PJ ;
Robertson, DW ;
Zaczek, R .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (09) :1641-1660